198 related articles for article (PubMed ID: 25450473)
1. Management of newer medications for attention-deficit/hyperactivity disorder in commercial health plans.
Hodgkin D; Horgan CM; Quinn AE; Merrick EL; Stewart MT; Leslie LK
Clin Ther; 2014 Dec; 36(12):2034-2046. PubMed ID: 25450473
[TBL] [Abstract][Full Text] [Related]
2. Management of Newer Antidepressant Medications in U.S. Commercial Health Plans.
Hodgkin D; Horgan CM; Creedon TB; Merrick EL; Stewart MT
J Ment Health Policy Econ; 2015 Dec; 18(4):165-73. PubMed ID: 26729008
[TBL] [Abstract][Full Text] [Related]
3. Management of access to branded psychotropic medications in private health plans.
Hodgkin D; Horgan CM; Garnick DW; Len Merrick E; Volpe-Vartanian J
Clin Ther; 2007 Feb; 29(2):371-80. PubMed ID: 17472830
[TBL] [Abstract][Full Text] [Related]
4. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
[TBL] [Abstract][Full Text] [Related]
5. Medication costs to private insurers of diversion of medications for attention-deficit hyperactivity disorder.
Aldridge AP; Kroutil LA; Cowell AJ; Reeves DB; Van Brunt DL
Pharmacoeconomics; 2011 Jul; 29(7):621-35. PubMed ID: 21473655
[TBL] [Abstract][Full Text] [Related]
6. An early examination of access to select orphan drugs treating rare diseases in health insurance exchange plans.
Robinson SW; Brantley K; Liow C; Teagarden JR
J Manag Care Spec Pharm; 2014 Oct; 20(10):997-1004. PubMed ID: 25278322
[TBL] [Abstract][Full Text] [Related]
7. Relationship of the use and costs of physician office visits and prescription drugs to travel distance and increases in member cost share.
Cecil WT; Barnes J; Shea T; Coulter SL
J Manag Care Pharm; 2006 Oct; 12(8):665-76. PubMed ID: 17269845
[TBL] [Abstract][Full Text] [Related]
8. Medicaid Prior Authorization Policies for Medication Treatment of Attention-Deficit/Hyperactivity Disorder in Young Children, United States, 2015.
Hulkower RL; Kelley M; Cloud LK; Visser SN
Public Health Rep; 2017; 132(6):654-659. PubMed ID: 29072963
[TBL] [Abstract][Full Text] [Related]
9. Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers.
Lin DH; Jones CM; Compton WM; Heyward J; Losby JL; Murimi IB; Baldwin GT; Ballreich JM; Thomas DA; Bicket M; Porter L; Tierce JC; Alexander GC
JAMA Netw Open; 2018 Jun; 1(2):e180235. PubMed ID: 30646077
[TBL] [Abstract][Full Text] [Related]
10. Attention-Deficit/Hyperactivity Disorder Medication Prescription Claims Among Privately Insured Women Aged 15-44 Years - United States, 2003-2015.
Anderson KN; Ailes EC; Danielson M; Lind JN; Farr SL; Broussard CS; Tinker SC
MMWR Morb Mortal Wkly Rep; 2018 Jan; 67(2):66-70. PubMed ID: 29346342
[TBL] [Abstract][Full Text] [Related]
11. Member satisfaction related to self-reported cost share and difficulty in obtaining prescription drugs in a university pharmacy benefit plan.
Nau DP; Chi C; Mallya U; Kirking DM
J Manag Care Pharm; 2007 Mar; 13(2):135-41. PubMed ID: 17330974
[TBL] [Abstract][Full Text] [Related]
12. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
Foy JM; Earls MF
Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
[TBL] [Abstract][Full Text] [Related]
13. Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs.
Fairman KA; Motheral BR; Henderson RR
Clin Ther; 2003 Dec; 25(12):3147-61; discussion 3144-6. PubMed ID: 14749153
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy for incident attention-deficit/hyperactivity disorder: practice patterns and quality metrics.
Bussing R; Narwaney KJ; Winterstein AG; Newton DA; DeBar L; Boscarino JA; Toh S; Pawloski P; Nordin JD; Herrinton LJ; Mason D; Daley MF
Curr Med Res Opin; 2014 Aug; 30(8):1687-99. PubMed ID: 24635013
[TBL] [Abstract][Full Text] [Related]
15. Access to Addiction Pharmacotherapy in Private Health Plans.
Reif S; Horgan CM; Hodgkin D; Matteucci AM; Creedon TB; Stewart MT
J Subst Abuse Treat; 2016 Jul; 66():23-9. PubMed ID: 27211993
[TBL] [Abstract][Full Text] [Related]
16. Indication and use of drug products used to treat attention-deficit/hyperactivity disorder: a cross-sectional study with inference on the likelihood of treatment in adulthood.
Brinker A; Mosholder A; Schech SD; Burgess M; Avigan M
J Child Adolesc Psychopharmacol; 2007 Jun; 17(3):328-33. PubMed ID: 17630866
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations.
Molife C; Bernauer MJ; Farr AM; Haynes VS; Kelsey D
Postgrad Med; 2012 Sep; 124(5):7-22. PubMed ID: 23095422
[TBL] [Abstract][Full Text] [Related]
18. Formulary tier placement for commonly prescribed branded drugs: benchmarking and creation of a preferred placement index.
Mullins CD; Palumbo FB; Saba M
Am J Manag Care; 2007 Jun; 13(6 Pt 2):377-84. PubMed ID: 17567239
[TBL] [Abstract][Full Text] [Related]
19. Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.
Lachaine J; Sikirica V; Mathurin K
BMC Psychiatry; 2016 Jan; 16():11. PubMed ID: 26774811
[TBL] [Abstract][Full Text] [Related]
20. The effect of incentive-based formularies on prescription-drug utilization and spending.
Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Frank RG
N Engl J Med; 2003 Dec; 349(23):2224-32. PubMed ID: 14657430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
